Astragaloside IV and echinacoside benefit neuronal properties via direct effects and through upregulation of SOD1 astrocyte function in vitro

Tian, Yang; Jin, Shijie; Promes, Vanessa; Liu, Xuemei; Zhang, Yunling

doi:10.1007/s00210-020-02022-w

Cited by 6 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have also confirmed that aS-iV alleviates neuron and Schwann cell damage and improves neural functional deficits (51)(52)(53), which significantly improves neurodegenerative diseases, such as alzheimer's disease (ad) and Pd (54). Moreover, aS-iV has demonstrated favorable therapeutic effects on neuromuscular disorders, such as amyotrophic lateral sclerosis (alS), which has been attributed to its ability to ameliorate inflammatory responses and neurotransmission (29,34,55,56). Since MG is a representative neuromuscular disease (57), it is reasonable to speculate that aS-iV may offer therapeutic effects in its management.…”

Section: Discussionmentioning

confidence: 99%

Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis

Zhang,

Huang,

Lan

et al. 2024

Mol Med Rep

View full text Add to dashboard Cite

astragaloside iV (aS-iV) has various pharmacological effects, including antioxidant and immunoregulatory properties, which can improve myasthenia gravis (MG) symptoms. However, the potential mechanism underlying the effects of aS-iV on MG remains to be elucidated. The present study aimed to investigate whether aS-iV has a therapeutic effect on MG and its potential mechanism of action. By subcutaneously immunizing rats with r97-116 peptide, an experimental autoimmune (ea) MG rat model was established. aS-iV (40 or 80 mg/kg/day) treatment was then applied for 28 days after modeling. The results demonstrated that aS-iV significantly ameliorated the weight loss, Lennon score and pathological changes in the gastrocnemius muscle of eaMG rats compared with the model group. additionally, the levels of acetylcholine receptor antibody (AChR-Ab) were significantly decreased, whereas mitochondrial function [aTPase and cytochrome c (cyt-c) oxidase activities] and ultrastructure were improved in the aS-iV treated rats. Moreover, the mrna and protein expression levels of phosphatase and tensin homolog-induced putative kinase 1, Parkin, lc3ii and Bcl-2, key signaling molecules for mitophagy and apoptosis, were upregulated, whereas the mrna and protein expression levels of p62, cyt-c, Bax, caspase 3 and caspase 9 were downregulated following aS-iV intervention. in conclusion, aS-iV may protect against eaMG in a rat model by modulating mitophagy and apoptosis. These findings indicated the potential mechanism underlying the effects of aS-iV on MG and provided novel insights into treatment strategies for MG.

show abstract

Section: Discussionmentioning

confidence: 99%

Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis

Zhang,

Huang,

Lan

et al. 2024

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…Electromagnetic radiation included mitochondrial degenerations, fewer synapses, and shorter postsynaptic densities (Li et al, 2012). The results showed that AS‐IV and echinacoside (ECH) can improve neuronal properties and rescue certain dysfunctions of astrocytes under superoxide dismutase 1 conditions, such as low expression of glutamate transporter 1 and loss of neuron‐supporting function (Tian, Jin, et al, 2021). AS‐IV downregulates the expression of interleukin‐17 via the Wnt pathway exerting cognitive benefits and promoting hippocampal neurogenesis in stroke mice (Sun et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Astragaloside IV ameliorates radiation‐induced nerve cell damage by activating the BDNF/TrkB signaling pathway

Liu

Ding

Jiang

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Radiation can induce nerve cell damage. Synapse connectivity and functionality are thought to be the essential foundation of all cognitive functions. Therefore, treating and preventing damage to synaptic structure and function is an urgent challenge. Astragaloside IV (AS‐IV) is a glycoside extracted from Astragalus membranaceus (Fisch.). Bunge is a widely used traditional Chinese medicine in China with various pharmacological properties, including protective effects on the central nervous system (CNS). In this study, the effect of AS‐IV on synapse damage and BDNF/TrkB signaling pathway in radiated C57BL/6 mice with X‐rays was investigated. PC12 cells and primary cortical neurons were exposed to UVA in vitro. Open field test and rotarod test were used to observe the effects of AS‐IV on the motor and explore the abilities of radiated mice. The pathological changes in the brain were observed by hematoxylin and eosin and Nissl staining. Immunofluorescence analysis was used to detect the synapse damage. The expressions of the BDNF/TrkB pathway and neuroprotection‐related molecules were detected by Western blotting and Quantitative‐RTPCR, respectively. The results showed that AS‐IV could improve the motor and explore abilities of radiated mice, reduce pathological damage to the cortex, enhance neuroprotection functions, and activate BDNF/TrkB pathway. In conclusion, AS‐IV could relieve radiation‐induced synapse damage, at least partly through the BDNF/TrkB pathway.

show abstract

“…[ 6 ] improving neuronal function. [ 7 ] delaying neurodegenerative diseases, and so on. [ 8 ] Furthermore, our previous experimental research disclosed that the compound containing AM could improve the cognitive function of VCI.…”

Section: Introductionmentioning

confidence: 99%

Exploring the target and molecular mechanism of Astragalus membranaceus in the treatment of vascular cognitive impairment based on network pharmacology and molecular docking

et al. 2023

View full text Add to dashboard Cite

Astragalus membranaceus (AM) is a traditional Chinese herbal medicine extensively utilized in vascular cognitive impairment (VCI) treatment. However, due to the complex components of AM, its exact molecular mechanism remains unclear. Therefore, this study investigated the target and molecular mechanism of AM to treat VCI based on network pharmacology and molecular docking. Firstly, the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, STITCH, and SwissTargetPrediction were utilized to gather the primary active ingredients of AM. The potential therapeutic targets of VCI were collected through GeneCards, OMIM, and DisGeNET databases. Secondly, the protein–protein interaction network was built using the STRING database. The enrichment analysis of gene ontology and the Kyoto Encyclopedia of Genes and Genome pathways was carried out in the R language. Finally, The network topology calculation of Cytoscape software was combined with module analysis to predict the binding properties of its active ingredients and targets. Twenty effective compounds and 733 targets were screened from AM, among which 158 targets were seen as possible targets of AM to treat VCI. MAPK3 and MMP9 were the critical targets of AM intervention in VCI. The crucial pathways include PI3K/Akt, MAPK, Rap1, and Ras signaling pathways. Besides, calycosin and quercetin might be the potential active compounds of AM for VCI treatment. AM intervenes in VCI through a multi-ingredient, multi-target, and multi-pathway coordination mechanism. These findings provide a foundation for a deeper understanding of the molecular mechanisms by which AM is effective in treating VCI.

show abstract

Astragaloside IV and echinacoside benefit neuronal properties via direct effects and through upregulation of SOD1 astrocyte function in vitro

Cited by 6 publications

References 44 publications

Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis

Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis

Astragaloside IV ameliorates radiation‐induced nerve cell damage by activating the BDNF/TrkB signaling pathway

Exploring the target and molecular mechanism of Astragalus membranaceus in the treatment of vascular cognitive impairment based on network pharmacology and molecular docking

Contact Info

Product

Resources

About